(UroToday.com) PARP inhibitors have shown promise in mCRPC patients with mutations in DNA repair, but ATM- and BRCA2-altered patients may respond differently to PARP inhibitors. Both rucaparib and olaparib were approved in May 2020 for BRCA2 and homologous recombination repair (HRR) gene-mutated mCRPC, respectively. However, the sequencing and efficacy of therapies in HRR-mutated mCRPC is not well-established. At the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting, Dr. Christopher Su and colleagues presented results of their study assessing differences that may also exist for taxane therapy, aiding in treatment sequencing decisions.